Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2024-11-26 Regulatory Filings
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Distributor Signed, Remplir Sales in Singapore to Commence 3 pages 235.3KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the appointment of an exclusive distributor for Orthocell's medical device Remplir in Singapore, detailing the company's international commercial expansion plans, regulatory approvals, and expected sales launch. It contains no financial statements, earnings data, or detailed financial analysis. It is not a report but an announcement of a business development and market expansion. There is no indication of it being a regulatory filing, audit report, or management discussion. The content fits best under a general regulatory announcement or business update category. Given the absence of financial data or report content, the most appropriate classification is Regulatory Filings (RNS).
2024-11-26 English
Key Executives Appointed to Drive Remplir US Sales 3 pages 233.2KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of two key US-based executives to support the commercial launch of Orthocell's product Remplir™ in the US market. It discusses the company's strategy, market opportunity, and preparations for FDA approval and sales launch. There are no financial statements, detailed financial performance data, or regulatory filings such as 10-K or interim reports. The content focuses on management appointments and strategic business updates related to commercialization efforts. This fits best under Board/Management Information (MANG) as it announces changes in senior management roles relevant to the company's operations and market expansion.
2024-11-10 English
Letter, Supp Notice of Meeting & Replacement Proxy Form 14 pages 579.6KB
AGM Information Classification · 100% confidence The document is a Supplementary Notice of Annual General Meeting (AGM) for Orthocell Limited, dated November 2024. It includes details about additional resolutions to be voted on at the AGM, proxy form instructions, and explanatory memorandum related to share placement and ratification of share issues. The content is focused on meeting logistics, shareholder voting, and capital raising resolutions, which are typical for AGM materials. There is no financial statement or detailed financial analysis present, nor is it a full annual report or earnings release. The document is not a simple announcement of a report but the actual supplementary meeting notice and proxy form, which are materials shared during the AGM process. Therefore, the correct classification is AGM Information (AGM-R).
2024-11-06 English
Orthocell completes $17m Placement 2 pages 183.5KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of a $17 million placement by Orthocell Limited to fund the US launch of a product and further growth. It details the placement size, share issuance, use of proceeds, and includes forward-looking statements. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is focused on capital raising and financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 5866 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or earnings release.
2024-10-30 English
Application for quotation of securities - OCC 8 pages 20.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from Orthocell Limited regarding the application for quotation of newly issued securities on the ASX. It details the number and type of securities to be quoted, issue price, and issued capital following quotation. The document references a previous Appendix 3B announcement related to the securities issuance. The content is regulatory in nature, focused on the listing and quotation of shares rather than financial results or management commentary. It is not a financial report, earnings release, or management discussion. The document is a formal regulatory filing related to capital market activities, specifically the quotation of securities, which aligns with the category 'Share Issue/Capital Change (SHA)'. The document length (6147 characters) and detailed content confirm it is the actual announcement, not just a brief notice or report publication announcement.
2024-10-30 English
Cleansing Notice 1 page 128.1KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of new shares by Orthocell Limited. It details the number of shares issued, the issue price, and compliance with relevant sections of the Corporations Act. There is no financial report, earnings data, or detailed financial analysis present. The document is an announcement related to a capital raising event and share issuance, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and focused solely on the share issuance notice, confirming it is not a report publication announcement or regulatory filing of a different nature.
2024-10-30 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.